Skip to main content
. 2019 Sep 15;11(9):5457–5471.

Figure 1.

Figure 1

LncRNA FOXD2-AS1 is upregulated and significantly correlated with poor prognosis in thyroid cancer cohort from TCGA dataset. A. Expression levels of FOXD2-AS1 in different types of solid cancers were analyzed based on TCGA dataset. BLCA, bladder cancer; BRCA, breast cancer; CHOL, cholangiocarcinoma; COAD, colon cancer; ESCA, esophagus cancer; HNSC, head-Neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, renal cancer; KIRP, kidney renal papillary cell carcinoma; LIHC, liver cancer; LUAD, lung cancer; LUSC, Lung squamous Cell Carcinoma; PRAD, prostate adenocarcinoma; READ, rectal cancer; STAD, stomach cancer; THCA, thyroid cancer; UCEC, uterine Corpus endometrial carcinoma; B. Expression levels of FOXD2-AS1 in THCA and normal control tissues were analyzed based on TCGA THCA cohort. Data were presented as mean ± SD, Student’s t-test, **P<0.01. C. Expression levels of FOXD2-AS1 in TCGA THCA cohort with different TNM stages were analyzed. Data were presented as mean ± SD, Student’s t-test, **P<0.01. D, E. Correlation analysis between the expression levels of FOXD2-AS1 and Ki67 or PCNA. F, G. Kaplan-Meier analysis of overall survival (OS) or disease-free survival (DFS) in THCA cohort with high or low expression levels of FOXD2-AS1. H, I. Kaplan-Meier analysis of OS or DFS in THCA cohort with high or low expression levels of FOXD2-AS1 at different TNM stages. Survival analysis was evaluated using the Kaplan-Meier method and assessed using the log-rank test. *P<0.05 and **P<0.01.